Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 16 recruiting now later-stage tilt

Contraception: later-stage trial registry

16 of 73 indexed Contraception trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #188 of 28,707 conditions by registered trial count.

73 US clinical trials · 16 currently recruiting · #188 of 28,707 conditions by registered trial count

Contraception: 73 US clinical trials tracked, 16 recruiting.

Contraception is the subject of 73 registered US clinical trials on ClinicalTrials.gov, 16 of them currently open to new participants. 16 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is University of Utah, running 6 of these trials.

Enrollment posture brief

Registry condition contraception

OPEN 16 | RECR 22% | LATE 16 | EARLY 8 | RANK #188 | SPON 6

Nearest open-share peer: Cardiovascular Risk Factor (22% recruiting · 32 trials)

Solid Tumor, Adult65.8%Anatomic Stage II Breast Can54.1%Pulmonary Hypertension50.7%Contraception (this)22%Anemia18.9%
Open-enrollment share among volume-matched conditions near Contraception

Contraception lists 16 open slots (22% of 73 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Contraception on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Contraception is recruiting below its size-band peers.

    16 of 73 indexed trials (21.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Contraception trials is spread across many organizations.

    University of Utah accounts for 6 of 73 trials (8.2%). 42 distinct sponsors appear on at least one study for this condition label.

  3. Typical Contraception enrolment sits around 150 participants.

    Median target enrolment is 150 among the 73 trials that report a genuine target (sentinel values excluded). 30 of those (41.1%) plan for fewer than 100 participants.

  4. Contraception research is mostly interventional.

    57 interventional and 16 observational studies make up this index (78.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 17Phase 21Phase 34Phase 412

Open and recent trials

73 total, page 2 of 2

COMPLETED Phase 4 119 participants

A Study to Assess the Safety of a New Inserter Device for Paragard® (Intrauterine Copper Contraceptive)

CooperSurgical

NCT05309694

COMPLETED NA 116 participants

IUD Self-Removal: Evaluating an Online Guide for Self-removal in Clinical and Non-clinical Settings

University of Washington

NCT06042556

COMPLETED Phase 4 96 participants

Postpartum Etonogestrel Implant for Adolescents

University of North Carolina, Chapel Hill

NCT01666912

COMPLETED NA 84 participants

Video Counseling for Effective Postpartum Contraception

University of North Carolina, Chapel Hill

NCT02438800

COMPLETED NA 72 participants

Nitrous Oxide for Pain Management During In-office Transcervical Sterilization

University of New Mexi

NCT02312739

COMPLETED Phase 1 60 participants

A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age

Teva Branded Pharmaceutical Products R&D

NCT04682353

COMPLETED Phase 4 59 participants

Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk

Lisa Haddad

NCT02357368

COMPLETED Phase 2 52 participants

Effect of Norgestrel 75 mcg on Cervical Mucus and Ovarian Activity During Perfect Use, After One Delayed Intake and After a Missed Pill

HRA Pharma

NCT03585712

COMPLETED 52 participants

Contraception for Solid Organ Transplant Patients: Utilizing Social Media

University of California, San Diego

NCT03979950

COMPLETED NA 49 participants

Pilot Bi-Lateral Tubal Occlusion Trial for Female Permanent Contraception

Femasys

NCT03067272

COMPLETED NA 40 participants

Home or Office Visit for the Insertion of Implantable Birth Control

Case Western Reserve University

NCT01816932

COMPLETED NA 37 participants

Reducing Adolescent Pregnancy in the Emergency Department

Children's Mercy Hospital Kansas City

NCT04744155

COMPLETED Phase 4 36 participants

Impact of Combined Hormonal Contraceptives on UPA

Oregon Health and Science University

NCT02577601

COMPLETED NA 30 participants

High-risk Obstetrical Patient Intervention Utilizing the Contraceptive CHOICE Project Script

University of California, San Diego

NCT03049592

COMPLETED Early Phase 1 25 participants

Inpatient Adolescent Contraception

Children's Mercy Hospital Kansas City

NCT04423068

COMPLETED 18 participants

Pharmacokinetics of Implanon in Obese Women

University of Chicago

NCT00724438

COMPLETED Phase 1 17 participants

Pharmacokinetic and Pharmacodynamic Study of Cyclofem

Sun Pharmaceutical Industries Limited

NCT01699022

COMPLETED NA 17 participants

Group Versus Individual Contraceptive Counseling for Resettled African Refugee Women

University of Utah

NCT02796586

COMPLETED Phase 1 16 participants

ORAL T-6: Oral Androgens in Man-6

University of Washington

NCT00663793

COMPLETED 13 participants

Changes in Vaginal, Cervical and Uterine Microflora With Levonorgestrel Intrauterine Device Placement

University of Utah

NCT01496898

COMPLETED Phase 1 12 participants

Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle

Teva Branded Pharmaceutical Products R&D

NCT02817464

COMPLETED Phase 4 8 participants

Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)

University of Washington

NCT00194649

COMPLETED Phase 4 7 participants

Intrauterine Contraceptive Device (IUD) Placement at Time of C-Section

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

NCT00733278

← Previous Page 2 of 2

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 1
Phase 3 4
Phase 4 12

Named interventions

Most-linked intervention names on Contraception records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

FemBloc Device
3 trials
Etonogestrel implant Drug
2 trials
Multi-Level Intervention Behavioral
1 trials
Norethindrone/ethinyl estradiol Drug
1 trials
ellaOne® (ulipristal acetate) Drug
1 trials
Interaction with non-IUC users only Behavioral
1 trials
Interaction with users of IUC and non-IUC users Behavioral
1 trials
Depo-subQ Provera Drug
1 trials

US sites by state

Facility locations filed on Contraception trials. A trial with sites in several states counts in each.

California 23 trials
Colorado 12 trials
Utah 9 trials
Missouri 9 trials
Washington 8 trials
Arizona 8 trials
Pennsylvania 7 trials
Ohio 7 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Contraception page

73 registered trials, 16 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Contraception condition card totals 73 registered trials; most-linked intervention FemBloc; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.